Royal Bank of Canada
AKBA icon

Royal Bank of Canada’s Akebia Therapeutics AKBA Stock Holding History

Royal Bank of Canada’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,052
Closed -$37K – 7056
2025
Q4 		$37K Sell
23,052
-3,726
-14% -$7.8K ﹤0.01% 5702
2025
Q3 		$73K Sell
26,778
-14,485
-35% -$48.2K ﹤0.01% 5657
2025
Q2 		$150K Buy
41,263
+26,931
+188% +$74K ﹤0.01% 5359
2025
Q1 		$28K Sell
14,332
-14,668
-51% -$29.9K ﹤0.01% 5796
2024
Q4 		$55K Buy
29,000
+8,179
+39% +$14.2K ﹤0.01% 5638
2024
Q3 		$27K Buy
20,821
+755
+4% +$1.01K ﹤0.01% 5987
2024
Q2 		$21K Buy
20,066
+19,828
+8,331% +$24.5K ﹤0.01% 6044
2024
Q1 		$0 Buy
238
+138
+138% +$221 ﹤0.01% 6962
2023
Q4 		$0 Buy
+100
New +$102 ﹤0.01% 7065
2023
Q3 		– Sell
-500
Closed – – 7036
2023
Q2 		$0 Buy
+500
New +$483 ﹤0.01% 7207
2022
Q4 		– Sell
-467
Closed – – 7177
2022
Q3 		$0 Sell
467
-120
-20% -$47 ﹤0.01% 7405
2022
Q2 		$0 Sell
587
-10,250
-95% -$4.3K ﹤0.01% 7329
2022
Q1 		$8K Sell
10,837
-24,958
-70% -$53.4K ﹤0.01% 7036
2021
Q4 		$80K Buy
35,795
+20,584
+135% +$56.1K ﹤0.01% 6088
2021
Q3 		$44K Buy
15,211
+3,219
+27% +$9.19K ﹤0.01% 6232
2021
Q2 		$45K Sell
11,992
-1,951
-14% -$6.57K ﹤0.01% 6104
2021
Q1 		$48K Sell
13,943
-60,745
-81% -$219K ﹤0.01% 5908
2020
Q4 		$209K Buy
74,688
+68,394
+1,087% +$200K ﹤0.01% 4824
2020
Q3 		$16K Buy
6,294
+4,756
+309% +$41.7K ﹤0.01% 5769
2020
Q2 		$21K Sell
1,538
-276
-15% -$2.85K ﹤0.01% 5566
2020
Q1 		$14K Sell
1,814
-6,493
-78% -$50.5K ﹤0.01% 5687
2019
Q4 		$52K Buy
8,307
+6,997
+534% +$33.3K ﹤0.01% 5431
2019
Q3 		$5K Sell
1,310
-866
-40% -$3.71K ﹤0.01% 6010
2019
Q2 		$10K Buy
2,176
+610
+39% +$3.47K ﹤0.01% 6016
2019
Q1 		$12K Hold
1,566
– – ﹤0.01% 5886
2018
Q4 		$8K Sell
1,566
-321
-17% -$2.51K ﹤0.01% 5976
2018
Q3 		$17K Buy
1,887
+1,027
+119% +$9.19K ﹤0.01% 5755
2018
Q2 		$9K Buy
860
+742
+629% +$7.43K ﹤0.01% 5848
2018
Q1 		$2K Sell
118
-450
-79% -$6.29K ﹤0.01% 6097
2017
Q4 		$9K Sell
568
-4,084
-88% -$67.7K ﹤0.01% 5893
2017
Q3 		$92K Buy
4,652
+3,878
+501% +$59.6K ﹤0.01% 5065
2017
Q2 		$10K Sell
774
-1,557
-67% -$19.7K ﹤0.01% 5785
2017
Q1 		$21K Sell
2,331
-11,058
-83% -$108K ﹤0.01% 5592
2016
Q4 		$140K Buy
13,389
+589
+5% +$5.07K ﹤0.01% 4698
2016
Q3 		$116K Hold
12,800
– – ﹤0.01% 4745
2016
Q2 		$96K Buy
12,800
+9,144
+250% +$79.8K ﹤0.01% 4803
2016
Q1 		$33K Sell
3,656
-16,330
-82% -$132K ﹤0.01% 5295
2015
Q4 		$258K Buy
19,986
+7,608
+61% +$77.6K ﹤0.01% 4341
2015
Q3 		$119K Sell
12,378
-12,880
-51% -$118K ﹤0.01% 4671
2015
Q2 		$260K Buy
25,258
+4,246
+20% +$36.2K ﹤0.01% 4163
2015
Q1 		$234K Buy
21,012
+18,912
+901% +$201K ﹤0.01% 4117
2014
Q4 		$24K Buy
2,100
+850
+68% +$12.2K ﹤0.01% 5344
2014
Q3 		$28K Sell
1,250
-19,700
-94% -$453K ﹤0.01% 5176
2014
Q2 		$582K Buy
+20,950
New +$504K ﹤0.01% 3278

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Royal Bank of Canada's AKBA Position: Q1 2026 in Review

Royal Bank of Canada sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 23,052 shares — an estimated $37K sold.

Royal Bank of Canada first reported a position in AKBA in Q2 2014 and held it in 44 quarters. The position peaked at $582K in Q2 2014. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Royal Bank of Canada reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 23,052 Akebia Therapeutics shares in Q1 2026, an estimated $37K.
  • Royal Bank of Canada first reported a position in Akebia Therapeutics in Q2 2014 and held it in 44 quarters.
  • Royal Bank of Canada's Akebia Therapeutics position peaked at $582K in Q2 2014.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.